Literature DB >> 791332

Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.

B F Johnson, J LaBrooy, A D Munro-Faure.   

Abstract

1 The interaction of phentolamine with the beta-adrenoreceptor-blocking drug, oxprenolol, was studied in a controlled trial. 2 The combination was generally well tolerated. 3 Oxprenolol alone produced modest but significant reductions in supine, standing and post-exercise blood pressures. Small reductions were observed only with sustained phentolamine administration. 4 The combined effect of the two drugs seemed to be addictive only at the lower level of oxyprenolol dosage. 5 Labetalol produced significantly greater reductions in supine and standing blood pressure than combined oxprenolol-phentolamine. At a daily dose of 400 mg, postural hypotension was not observed, although transient symptoms were frequent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 791332

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Circulatory and alpha-adrenoceptor blocking effects of phentolamine.

Authors:  D A Richards; E P Woodings; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  [Acute combined alpha- and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and aldosterone].

Authors:  U Grüninger; R Akert; H Hunkeler; E Wegmüller; P Weidmann; J Hodler
Journal:  Klin Wochenschr       Date:  1979-07-15

4.  Labetalol in essential hypertension.

Authors:  A Breckenridge; M Orme; M J Serlin; M Maciver
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors.

Authors:  B J Milne; A G Logan
Journal:  Can Med Assoc J       Date:  1980-11-22       Impact factor: 8.262

6.  Comparison of labetalol and propranolol in hypertension.

Authors:  D P Nicholls; M H Husaini; C J Bulpitt; M D Stephens; A G Butler
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

7.  Labetalol, a cross-over double blind controlled trial.

Authors:  G L Sanders; P A Routledge; J G Rao; G M Gales; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

Review 8.  Alpha- and beta-blockade in angina pectoris.

Authors:  S H Taylor
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Direct vasodilatation by labetalol in anaesthetized dogs.

Authors:  R C Dage; C P Hsieh
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

10.  A comparative study of methyldopa and labetalol in the treatment of hypertension.

Authors:  G L Sanders; D M Davies; G M Gales; J G Rao; M D Rawlins; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.